Wednesday, June 7, 2023
LBNN
  • Home
  • Business
  • Technology
  • Investigative journalism
  • Health
  • Politics
  • Art & Culture
  • Sports
  • Crypto
  • Entertainment
No Result
View All Result
LBNN
Home Politics

NPFL: Remo Stars unveil ex-NPFL top scorer, Lokosa

Simon Osuji by Simon Osuji
March 23, 2023
in Politics
0
NPFL: Remo Stars unveil ex-NPFL top scorer, Lokosa
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Remo Stars have unveiled former Nigeria Premier Football League top scorer, Junior Lokosa.

Related posts

Empowering the Interpol network of global law enforcement cooperation

Empowering the Interpol network of global law enforcement cooperation

June 7, 2023
Optiven Tree Planting at Achiever’s Paradise-Kimuka, Ngong’

Optiven Tree Planting at Achiever’s Paradise-Kimuka, Ngong’

June 7, 2023

Lokosa linked up with the Sky Blue Stars after severing ties with Qatari club, Al- Rayyan.

The forward was the top scorer in the NPFL in 2018, netting 19 times.

DAILY POST exclusively reported last week that the 29-year-old forward was spotted at the Remo Stars Stadium in Ikenne

According to reports, Lokosa will earn around N700,000 monthly at Remo Stars.

Lokosa had a brief stint with Kwara United before returning to Qatar last season.

He started his career with First Bank Football Club of Lagos.

NPFL: Remo Stars unveil ex-NPFL top scorer, Lokosa

Source link

Previous Post

TikTok Star, Jehane Thomas Dies At 30

Next Post

Can the Fed Rate Hike Amid Banking Turmoil Boost BTC and ETH?

Next Post
Can the Fed Rate Hike Amid Banking Turmoil Boost BTC and ETH?

Can the Fed Rate Hike Amid Banking Turmoil Boost BTC and ETH?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Nicki Minaj Calls Out Yung Miami Over ‘Caresha Please’ Promo

Nicki Minaj Calls Out Yung Miami Over ‘Caresha Please’ Promo

2 weeks ago
BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

2 weeks ago
Recombinant and tunable spidroin hydrogels for drug release and cell culture

Recombinant and tunable spidroin hydrogels for drug release and cell culture

5 days ago
Law seeking to recognise intersex as third gender drafted

Law seeking to recognise intersex as third gender drafted

1 day ago

BROWSE BY CATEGORIES

  • Art & Culture
  • Business
  • Crypto
  • Entertainment
  • Health
  • Investigative journalism
  • Politics
  • Sports
  • Technology

POPULAR NEWS

  • There’s Something Terribly Wrong With Gorsad Kyiv and it’s Worse than Balenciaga

    There’s Something Terribly Wrong With Gorsad Kyiv and it’s Worse than Balenciaga

    0 shares
    Share 0 Tweet 0
  • Pfizer’s Depopulation Agenda, As Evidenced By Its Own Documents

    0 shares
    Share 0 Tweet 0
  • Leaked Pentagon Document Shows How Ukraine War Is Bleeding Into Middle East

    0 shares
    Share 0 Tweet 0
  • The Occult Meaning of “Guillermo del Toro’s Pinocchio”

    0 shares
    Share 0 Tweet 0
  • The 2023 MET Gala: A Ridiculous Parade of Industry Slaves

    0 shares
    Share 0 Tweet 0

Category

  • Art & Culture
  • Business
  • Crypto
  • Entertainment
  • Health
  • Investigative journalism
  • Politics
  • Sports
  • Technology

Recent Posts

Trump denies reports claiming DOJ told him of imminent indictment

Trump denies reports claiming DOJ told him of imminent indictment

June 7, 2023

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

June 7, 2023
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Technology
  • Investigative journalism
  • Health
  • Politics
  • Art & Culture
  • Sports
  • Crypto
  • Entertainment

© 2023 LBNN - All rights reserved.